The Expanding Role of CAR T Cells in Lymphoma and Leukemia - Episode 8
Stephen J. Schuster, MD: When are we going to have it for follicular, bad follicular lymphoma and bad marginal zone lymphoma, because as we said earlier, these do exist?
Caron A. Jacobson, MD: Yes. I’m optimistic that 2021 may be a year for follicular lymphoma at least, so that we presented the results of ZUMA-5 (NCT03105336) at [American Society of Clinical Oncology] on Friday. This included up to 125 patients with follicular lymphoma, 80 of whom were evaluable for efficacy, because I had at least 9-month follow-up. Then we added additional 16 patients out of a planned 35 patients with marginal zone lymphoma, all third-line and beyond. They all had to have a CD20 monoclonal antibody, as well as an alkylating agent. These patients had median number of lines of prior therapy, 3 or more, 70% of patients have had 3 or more prior lines of therapy.More than half the patients had a high FLIPI (Follicular Lymphoma International Prognostic Index). They had high tumor burden by GELF (Groupe d’Etude des Lymphomes Folliculaires) criteria. It’s a high-risk population. The overall response rate for follicular lymphoma was 95%, and the CR [complete remission] rate was 81%. And if you looked to the median follow-up for that cohort at 15.8 months, 80% of patients who achieved a CR maintained their CR. Again, [as] with mantle cell lymphoma, we need much longer follow-up to understand what the natural history of this disease will be after CAR T cells, but definitely longer than other available options for patients in this line of therapy.
Transcript Edited for Clarity